The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 06, 2016

Filed:

Dec. 15, 2015
Applicant:

Signal Pharmaceuticals, Llc, San Diego, CA (US);

Inventors:

Gerald Scott Barden Horan, Winchester, MA (US);

Ying Ye, Martinsville, NJ (US);

Assignee:

Signal Pharmaceuticals, LLC, San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 31/505 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6881 (2013.01); A61K 9/0053 (2013.01); A61K 31/505 (2013.01); G01N 2333/4706 (2013.01); G01N 2440/14 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyzes allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.


Find Patent Forward Citations

Loading…